Pruebas inmunoquímicas fecales (PIF) para determinar la hemoglobina en la evaluación de pacientes con síntomas abdominales inferiores: controversias actuales

TY - JOUR

T1 - Pruebas inmunoquímicas fecales (PIF) para determinar la hemoglobina en la evaluación de pacientes con síntomas abdominales inferiores

T2 - controversias actuales

AU - Fraser, Callum G.

PY - 2019/4

Y1 - 2019/4

N2 - Faecal immunochemical tests for haemoglobin (FIT), as an adjunct to clinical information, assist in the triage of patients presenting in primary care with lower abdominal symptoms. Controversy remains regarding whether and which qualitative and quantitative FIT can be used, which groups of patients would benefit most from FIT, whether FIT should be done in primary and/or secondary care, and how FIT should be incorporated into diagnostic pathways. Controversy also exists as to the optimum cut-off used for referral for colonoscopy. A single sample of faeces may be sufficient. Reporting of results requires consideration. FIT provide a good rule in test for colorectal cancer and a good rule out test for significant bowel disease, but robust safety-netting is required for patients with negative results and ongoing symptoms. Risk scoring models have been developed, but their value is unclear as yet. Further evaluation of these topics is required to inform good practice.

AB - Faecal immunochemical tests for haemoglobin (FIT), as an adjunct to clinical information, assist in the triage of patients presenting in primary care with lower abdominal symptoms. Controversy remains regarding whether and which qualitative and quantitative FIT can be used, which groups of patients would benefit most from FIT, whether FIT should be done in primary and/or secondary care, and how FIT should be incorporated into diagnostic pathways. Controversy also exists as to the optimum cut-off used for referral for colonoscopy. A single sample of faeces may be sufficient. Reporting of results requires consideration. FIT provide a good rule in test for colorectal cancer and a good rule out test for significant bowel disease, but robust safety-netting is required for patients with negative results and ongoing symptoms. Risk scoring models have been developed, but their value is unclear as yet. Further evaluation of these topics is required to inform good practice.

KW - Colorectal cancer

KW - Faecal haemoglobin

KW - Faecal immunochemical test

KW - Faecal occult blood test

KW - Lower abdominal symptoms

KW - Significant bowel disease

UR - https://www.scopus.com/pages/publications/85056631923

U2 - 10.1016/j.gastrohep.2018.09.007

DO - 10.1016/j.gastrohep.2018.09.007

M3 - Article

C2 - 30459060

AN - SCOPUS:85056631923

SN - 0210-5705

VL - 42

SP - 263

EP - 270

JO - Gastroenterologia y Hepatologia

JF - Gastroenterologia y Hepatologia

IS - 4

ER -